Common data elements for clinical research in mitochondrial disease: a National Institute for Neurological Disorders and Stroke project
Tóm tắt
The common data elements (CDE) project was developed by the National Institute of Neurological Disorders and Stroke (NINDS) to provide clinical researchers with tools to improve data quality and allow for harmonization of data collected in different research studies. CDEs have been created for several neurological diseases; the aim of this project was to develop CDEs specifically curated for mitochondrial disease (Mito) to enhance clinical research. Nine working groups (WGs), composed of international mitochondrial disease experts, provided recommendations for Mito clinical research. They initially reviewed existing NINDS CDEs and instruments, and developed new data elements or instruments when needed. Recommendations were organized, internally reviewed by the Mito WGs, and posted online for external public comment for a period of eight weeks. The final version was again reviewed by all WGs and the NINDS CDE team prior to posting for public use. The NINDS Mito CDEs and supporting documents are publicly available on the NINDS CDE website (
https://commondataelements.ninds.nih.gov/
), organized into domain categories such as Participant/Subject Characteristics, Assessments, and Examinations. We developed a comprehensive set of CDE recommendations, data definitions, case report forms (CRFs), and guidelines for use in Mito clinical research. The widespread use of CDEs is intended to enhance Mito clinical research endeavors, including natural history studies, clinical trial design, and data sharing. Ongoing international collaboration will facilitate regular review, updates and online publication of Mito CDEs, and support improved consistency of data collection and reporting.
Tài liệu tham khảo
Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, Enns GM, Falk MJ, Goldstein AC, Gopal-Srivastava R, Gorman GS, Hersh SP, Hirano M, Hoffman FA, Karaa A, MacLeod EL, McFarland R, Mohan C, Mulberg AE, Odenkirchen JC, Parikh S, Rutherford PJ, Suggs-Anderson SK, Tang WH, Vockley J, Wolfe LA, Yannicelli S, Yeske PE, Coates PM (2016) Nutritional interventions in primary mitochondrial disorders: developing an evidence base. Mol Genet Metab 119(3):187–206
Chinnery PF (2014) Mitochondrial disorders overview. In: Pagon PA, Adam MP, Ardinger HH et al (eds) Gene reviews. University of Washington, Seattle
DiMauro S, Schon E (2003) Mitochondrial respiratory-chain diseases. N Engl J Med 348:2656–2668
Gorman GS, Schaefer AM, Ng Y et al (2015) Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 77:753–759
Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM (2016) Mitochondrial diseases. Nat Rev Dis Primers. doi:10.1038/nrdp.2016.80
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S (2012) National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials 9:322–329
Harrison SM, Riggs ER, Maglott DR, Lee JM, Azzariti DR, Niehaus A, Ramos EM, Martin CL, Landrum MJ, Rehm HL (2016) Using ClinVar as a resource to support variant interpretation. Curr Protoc Hum Genet 89:8.16.1–8.16.23
Lott MT, Leipzig JN, Derbeneva O, Xie HM, Chalkia D, Sarmady M, Procaccio V, Wallace DC (2013) mtDNA variation and analysis using mitomap and mitomaster. Curr Protoc Bioinformatics 44:1.23.1–26
MacArthur DG, Manolio TA, Dimmock DP (2014) Guidelines for investigating causality of sequence variants in human disease. Nature 24 508(7497):469–476
Nightingale H, Pfeffer G, Bargiela D, Horvath R, Chinnery PF (2016) Emerging therapies for mitochondrial disorders. Brain 139:1633–1648
Niyazov D, Kahler S, Frye R (2016) Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for diagnosis and treatment. Mol Syndromol 7:122–137
Parikh S, Goldstein A, Koenig MK et al (2015) Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 17:689–701
Rahman S (2015) Emerging aspects of treatment in mitochondrial disorders. J Inherit Metab Dis 38:641–653
Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424
Suomalainen A (2013) Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders. Expert Opin Med Diagn 7:313–317
Yatsuga S, Fujita Y, Ishii A et al (2015) Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol 7:814–823